Compare iShares MSCI Japan ETF (EWJ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs TransMedics Group Inc — how do they compare? iShares MSCI Japan ETF trades at $97.86 (market cap $23.87B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: iShares MSCI Japan ETF is far larger — about 8.7× TransMedics Group Inc's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and TransMedics Group Inc for 24 Days on average.
| EWJ | TMDX | |
|---|---|---|
Market Cap | $23.87B | $2.74B |
Volume | 5,412,820 | 949,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $150.42 |
52-Week Low | $78.36 | $61.99 |
Typical Hold Time | 56 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.32, down 1.02% on the day. Technical indicators show a neutral overall signal with mixed moving averages and oscillators. Recent news highlights Japan's monetary policy uncertainty as the Bank of Japan navigates rate hikes amid fiscal stimulus concerns. The ETF remains positioned within a tight trading range between $96 support and $99 resistance levels.
Outlook remains cautious as Japan faces monetary tightening headwinds while maintaining fiscal stimulus. Investment opportunity exists in Japan's AI and semiconductor exposure, though currency volatility and rising bond yields present near-term risks. The neutral technical stance suggests limited directional momentum pending clearer policy signals from Japanese authorities.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
